HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
July 10, 2024 03:00 ET
|
HepaRegeniX GmbH
Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regenerationElias Papatheodorou moves from Chair of the Board to CEO of...